3

résultat(s)

Mot(s)
Type de publication
Domaine politique
Mot-clé
Date

Disease Mongering (Pseudo-Disease Promotion)

15-11-2012

Disease mongering is the promotion of pseudo-diseases by the pharmaceutical industry aiming at economic benefit. Medical equipment manufacturers, insurance companies, doctors or patient groups may also use it for monetary gain or influence. It has increased in parallel with society's 'medicalisation' and the growth of the pharmaceutical complex. Due to massive investments in marketing and lobbying, ample use of internet and media, and the emergence of new markets, it is becoming a matter of concern ...

Disease mongering is the promotion of pseudo-diseases by the pharmaceutical industry aiming at economic benefit. Medical equipment manufacturers, insurance companies, doctors or patient groups may also use it for monetary gain or influence. It has increased in parallel with society's 'medicalisation' and the growth of the pharmaceutical complex. Due to massive investments in marketing and lobbying, ample use of internet and media, and the emergence of new markets, it is becoming a matter of concern, and policy makers should be aware of its perils and consequences.

Atelier "La santé dans toutes les politiques (approche HIAP)"

15-08-2011

Pendant de nombreuses années, les conséquences sur la santé de la nouvelle législation ont été prises en compte au cours du processus d'élaboration des politiques dans des domaines comme l'agriculture, l'environnement, les denrées alimentaires, etc. L'intégration des questions de santé dans toutes les politiques est désormais consacrée par le traité de Lisbonne (article 168). L'objectif de cet atelier a été de communiquer des informations actualisées sur la façon dont le système fonctionne actuellement ...

Pendant de nombreuses années, les conséquences sur la santé de la nouvelle législation ont été prises en compte au cours du processus d'élaboration des politiques dans des domaines comme l'agriculture, l'environnement, les denrées alimentaires, etc. L'intégration des questions de santé dans toutes les politiques est désormais consacrée par le traité de Lisbonne (article 168). L'objectif de cet atelier a été de communiquer des informations actualisées sur la façon dont le système fonctionne actuellement au sein des différents services de la Commission. Plusieurs représentants des directions générales, conduites par la DG SANCO, ont apporté leur contribution aux débats. Le cas des Pays-Bas, pris comme exemple afin d'illustrer le fonctionnement de ce système dans un État membre, a fait également l'objet d'une présentation.

Note on the Pharmaceutical Package for the EP Information Offices (EPIOs)

16-08-2010

The Pharmaceutical Package in this document refers to the initiatives taken by the European Commission under the "Communication on the future of the single market in pharmaceuticals for human use", setting out the EC's vision for the sector. It comprises three pieces of legislation put forward to the European Parliament on different aspects of medicinal products. The proposals cover: information to patients on prescription medicines, pharmacovigilance, and patient safety and falsified medicines. ...

The Pharmaceutical Package in this document refers to the initiatives taken by the European Commission under the "Communication on the future of the single market in pharmaceuticals for human use", setting out the EC's vision for the sector. It comprises three pieces of legislation put forward to the European Parliament on different aspects of medicinal products. The proposals cover: information to patients on prescription medicines, pharmacovigilance, and patient safety and falsified medicines. These legislative proposals have a direct impact on public health, as well as connections with internal market and industrial policies. In the European Parliament the Committee on Environment, Public Health and Food Safety-ENVI is leading these reports. The committees on the Internal Market-IMCO and Industry, Research & Energy-ITRE are responsible for opinions. This note provides a general overview of the present situation on public health policy and pharmaceutical products in the EU, taking into account its degree of implementation and impact. The note presents the three proposals from a public health perspective with regards to their present state of advancement inside the legislative process. Finally it mentions the main stakeholders for these subjects. The note includes an annex with the key officials responsible for this policy area in the EU institutions. IP/

Evénements à venir

20-01-2021
EPRS online policy roundtable with the World Bank: Where next for the global economy
Autre événement -
EPRS
25-01-2021
Public Hearing on "Gender aspects of precarious work"
Audition -
FEMM
27-01-2021
Public hearing on AI and Green Deal
Audition -
AIDA

Partenaires